Clinical and genetic research suggests that inhibiting sclerostin may increase the risk of cardiovascular diseases, as sclerostin produced in arterial tissue is thought to provide a protective mechanism against atherosclerosis [55]. The gene discussed is SOST; the disease is atherosclerosis.